Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Price:
23.92 USD
-3.86%
Market Closed
Updated:
May 29, 2024
Arrowhead Pharmaceuticals Inc
Total Current Liabilities
|
Arrowhead Pharmaceuticals Inc
Total Current Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
Total Current Liabilities
$65.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
20%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$41.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
21%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$13B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$19.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
See Also
What is Arrowhead Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
65.2m
USD
65.2m
USD
Based on the financial report for Mar 31, 2024, Arrowhead Pharmaceuticals Inc's Total Current Liabilities amounts to 65.2m USD.
What is Arrowhead Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
20%
20%
Over the last year, the Total Current Liabilities growth was -25%. The average annual Total Current Liabilities growth rates for Arrowhead Pharmaceuticals Inc have been -27% over the past three years , -9% over the past five years , and 20% over the past ten years .
You don't have any saved screeners yet
